Heron Therapeutics (HRTX) opened Q1 2026 with revenue of US$34.7 million, a basic EPS loss of US$0.04 and a net loss of US$8.1 million. On a trailing twelve month basis, the company recorded revenue of US$150.7 million and a basic EPS loss of US$0.18. Over recent quarters, revenue has moved between US$34.7 million and US$40.8 million, with quarterly basic EPS ranging from a profit of US$0.02 to a loss of US$0.10. This keeps the focus firmly on how quickly margins can tighten up from here.

See our full analysis for Heron Therapeutics.

With the headline numbers set, the next step is to see how these results line up with the widely shared narratives around Heron Therapeutics's growth potential, risks and path to profitability, and to assess where the latest margin picture pushes back against those stories.

Losses on TTM basis still sizeable at US$30.9 million

• On a trailing twelve month basis, Heron reported revenue of US$150.7 million and a net loss of US$30.9 million, compared with Q1 2026 revenue of US$34.7 million and a quarterly net loss of US$8.1 million, so the business is still funding a meaningful shortfall from operations.
• Bears focus on this ongoing cash burn and point out that net income for the last six reported quarters has swung between a profit of US$3.7 million and a loss of US$17.5 million. They argue this backs their concern that earnings stability is not yet in place.
  • Those same critics also highlight that trailing twelve month EPS sits at a loss of US$0.18, compared with positive quarterly EPS in late 2024, as evidence that profitability has not yet held up over a full year.
  • The bearish narrative links this pattern to the need for external financing and the risk of future dilution, which they see as a key issue for anyone looking at the stock around US$0.96 per share.

Over the last year of results, skeptics argue the swings between small profits and much larger losses underline how fragile the current earnings base is. They suggest readers weigh that against more cautious long term expectations before leaning on analyst price targets like US$3.67. 🐻 Heron Therapeutics Bear Case

Revenue forecasts at 13.9% vs ongoing quarterly swings

• Analysts are forecasting revenue growth of about 13.9% per year, yet reported quarterly revenue over the last six quarters has moved between US$34.7 million and US$40.8 million, which means the recent pattern is relatively flat compared with those forward looking expectations.
• What stands out for the bullish narrative is that, despite this tight revenue range and a trailing twelve month loss of US$30.9 million, analysts still model earnings growth of about 58.9% per year and expect a shift to profitability within three years.
  • Bulls often point to the multi year reduction in losses of about 46.9% per year as a sign that the current loss level may not tell the whole story about earnings potential.
  • At the same time, the gap between modest recent revenue movement and those double digit growth forecasts is exactly where execution risk sits, so these Q1 2026 numbers give you a concrete baseline to judge those optimistic assumptions.

Supporters of the optimistic view suggest Q1 2026 sits early in a multi year ramp. They add that the contrast between today’s flat looking revenue band and the 13.9% annual growth outlook is where upside could emerge if the rollout of core therapies tracks the stronger end of analyst models. 🐂 Heron Therapeutics Bull Case

Low 1.2x P/S against continued share dilution risk

• The stock is trading on a P/S of 1.2x using trailing twelve month revenue of US$150.7 million and a share price of about US$0.96, which is far below the cited peers at 19.6x and the US biotech industry average of 9.7x.
• Analysts' consensus view balances that low P/S against the fact that shareholders were diluted over the past year and that trailing twelve month EPS is a loss of US$0.18, so the case for any re rating depends heavily on whether the forecast move to roughly 24% margins within three years actually shows up in future filings.
  • On one side of the spectrum, bulls highlight the discounted sales multiple and model earnings in the tens of millions of US dollars by 2028, which they believe could justify higher prices than US$0.96 if achieved.
  • On the other, bears point back to the current US$30.9 million annual loss and recent need for higher cost financing as concrete reasons why that low multiple might also be compensating for real capital structure and execution risks.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Heron Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of risks and potential rewards feels finely balanced, treat it as your cue to move quickly, review the numbers, and decide where you stand by weighing the 3 key rewards and 2 important warning signs.

Explore Alternatives

Heron Therapeutics still reports sizeable losses, earnings swings and dilution risk, so the path to consistent profitability and balance sheet strength remains uncertain.

If you want ideas where financial footing and risk profiles look more resilient, start comparing against the 69 resilient stocks with low risk scores and see how those companies stack up right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.